1. Home
  2. SOWG vs XLO Comparison

SOWG vs XLO Comparison

Compare SOWG & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sow Good Inc.

SOWG

Sow Good Inc.

HOLD

Current Price

$3.23

Market Cap

69.9M

ML Signal

HOLD

XLO

Xilio Therapeutics Inc.

N/A

Current Price

$9.00

Market Cap

56.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SOWG
XLO
Founded
2010
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.9M
56.9M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
SOWG
XLO
Price
$3.23
$9.00
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$28.00
AVG Volume (30 Days)
14.9K
9.5K
Earning Date
05-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$43,766,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$168.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
589.88
52 Week Low
$0.10
$0.46
52 Week High
$4.45
$9.90

Technical Indicators

Market Signals
Indicator
SOWG
XLO
Relative Strength Index (RSI) 47.29 48.51
Support Level $2.45 $8.52
Resistance Level $3.65 $9.15
Average True Range (ATR) 0.27 0.29
MACD -0.01 -0.02
Stochastic Oscillator 5.28 57.33

Price Performance

Historical Comparison
SOWG
XLO

About SOWG Sow Good Inc.

Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats. The company operates in one reportable segment, reflecting its capital-light business model under which it earns proceeds from the sale of freeze-dried candy products.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Share on Social Networks: